278 related articles for article (PubMed ID: 21412164)
1. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
[TBL] [Abstract][Full Text] [Related]
2. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
[TBL] [Abstract][Full Text] [Related]
3. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
Prueksaritanond N; Chantape W
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
[TBL] [Abstract][Full Text] [Related]
4. Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary?
Peled Y; Aviram A; Krissi H; Gershoni A; Sabah G; Levavi H; Eitan R
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):498-502. PubMed ID: 26235227
[TBL] [Abstract][Full Text] [Related]
5. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?
Kwon JS; Abrams J; Sugimoto A; Carey MS
Int J Gynecol Cancer; 2008; 18(4):820-4. PubMed ID: 17892450
[TBL] [Abstract][Full Text] [Related]
6. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; McKee B; Hoskins WJ; Barakat RR
Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):79-85. PubMed ID: 12182977
[TBL] [Abstract][Full Text] [Related]
7. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
8. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
[TBL] [Abstract][Full Text] [Related]
9. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.
Solmaz U; Mat E; Ekin A; Gezer C; Biler A; Peker N; Ayaz D; Sanci M
Int J Surg; 2016 Aug; 32():71-7. PubMed ID: 27365052
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.
Creasman WT; Kohler MF; Odicino F; Maisonneuve P; Boyle P
Gynecol Oncol; 2004 Dec; 95(3):593-6. PubMed ID: 15581969
[TBL] [Abstract][Full Text] [Related]
11. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry.
Mattes MD; Lee JC; Metzger DJ; Ashamalla H; Katsoulakis E
J Gynecol Oncol; 2015 Jan; 26(1):19-24. PubMed ID: 25310855
[TBL] [Abstract][Full Text] [Related]
12. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.
Felix AS; Stone RA; Bowser R; Chivukula M; Edwards RP; Weissfeld JL; Linkov F
Int J Gynecol Cancer; 2011 Jul; 21(5):877-84. PubMed ID: 21666484
[TBL] [Abstract][Full Text] [Related]
13. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study.
Halperin R; Zehavi S; Langer R; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2002; 23(4):300-4. PubMed ID: 12214728
[TBL] [Abstract][Full Text] [Related]
14. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
[TBL] [Abstract][Full Text] [Related]
15. A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).
Chen L; Liu X; Li M; Wang S; Zhou H; Liu L; Cheng X
Cancer Med; 2020 Feb; 9(3):988-998. PubMed ID: 31846222
[TBL] [Abstract][Full Text] [Related]
16. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
17. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.
Hamilton CA; Cheung MK; Osann K; Chen L; Teng NN; Longacre TA; Powell MA; Hendrickson MR; Kapp DS; Chan JK
Br J Cancer; 2006 Mar; 94(5):642-6. PubMed ID: 16495918
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study.
Kim M; Kwon BS; Chang HK; Lee S; Chang SJ; Choi JY; Park SY; Lee M; Ryu HS; Kim YB
J Gynecol Oncol; 2019 May; 30(3):e44. PubMed ID: 30887761
[TBL] [Abstract][Full Text] [Related]
19. Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma.
Solmaz U; Ekin A; Mat E; Gezer C; Dogan A; Biler A; Peker N; Hasdemir PS; Sanci M
Tumori; 2016 Dec; 102(6):593-599. PubMed ID: 27514313
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma.
Lindahl B; Persson J; Ranstam J; Willén R
Anticancer Res; 2010 Sep; 30(9):3727-30. PubMed ID: 20944161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
